Brady Collins
Feline injection-site sarcomas (FISS) are a serious but uncommon adverse reaction to vaccines in cats. The development of FISS is associated with chronic inflammatory reactions at the site of injections, which can lead to malignant transformation and aggressive tumour growth. While the risk is estimated to be between 1 in 1000 and 1 in 10,000 vaccinations, it is important to consider ways to minimise this risk. Purevax, a non-adjuvanted canarypox-vectored rabies vaccine, has been introduced as an alternative to adjuvanted vaccines, which have been implicated in the development of FISS. This raises the question of whether Purevax has a lower risk of vaccine-site fibrosarcoma compared to other vaccines.
| Characteristics | Values |
|---|---|
| Risk of vaccine site fibrosarcoma | Uncommon but serious adverse reaction |
| Risk factors | Vaccine temperature, vaccine formulation, patient genetics |
| Tumor development latency period | 2 months to 10 years |
| Prevalence | 1 in 1,000 to 1 in 10,000 vaccinations |
| Treatment | Surgical excision, local immunotherapy, iridium-based brachytherapy |
| Prevention | Vaccination in lower distal limbs, non-adjuvanted vaccines |
Explore related products
What You'll Learn
- Feline injection-site sarcomas (FISS) are uncommon but serious adverse reactions
- Studies suggest vaccines and other injectables are risk factors for FISS
- Tumour removal is easier when the vaccine is administered in the lower distal limbs
- The risk of postvaccinal sarcoma is estimated at between 1 in 1,000 and 1 in 10,000 vaccinations
- The introduction of Purevax, the first non-adjuvanted canarypox-vectored rabies vaccine, in 2000
Feline injection-site sarcomas (FISS) are uncommon but serious adverse reactions
FISS is caused by malignant transformation of reactive fibroblasts at the periphery of a nodule of necrotizing and granulomatous cellulitis at the site of previous vaccination. The resulting tumour is a high-grade sarcoma, with considerable phenotypic variation. At least 80% are histologically classified as fibrosarcoma.
While vaccines can induce FISS, it is important to remember that any injection could potentially lead to an injection site sarcoma, and other injectables have been known to cause sarcoma formation. It is believed that the inflammation associated with vaccine administration is the main concern, rather than the disease-causing organisms themselves. This inflammation may be influenced by variables in vaccine formulation and genetically conditioned patient response.
To reduce the risk of FISS, veterinarians are placing vaccines in sites that would make tumour removal easier, such as the lower distal limbs or the tail, instead of the interscapular space.
Montessori School Attendance: Are Vaccinations Required?
You may want to see also
Explore related products
Studies suggest vaccines and other injectables are risk factors for FISS
Feline injection-site sarcomas (FISS) are aggressive neoplasms that have been associated with vaccination. While the risk of FISS is small, it has devastating consequences for both the patient and owner. The time from vaccination to tumour development is typically between 3 months and 4 years, with a smaller number of tumours developing 5 or more years after vaccination.
Recent studies suggest that vaccines and other injected agents are risk factors for FISS. These studies show that in some cats, the mere process of instilling a substance into the skin can induce inflammation. It is speculated that this inflammation is not controlled in some cats, which may explain the development of sarcomas. While the specific risk factors for FISS development are not yet known, it is thought that inflammatory processes related to the administration of injectable products can lead to sarcoma formation.
The role of adjuvants, including those containing aluminium, in the pathogenesis of FISS is unclear. Several authors have suggested that adjuvants present in inactivated feline vaccines licensed in the US cause chronic inflammation, which may trigger tumour formation in genetically predisposed cats. However, studies have failed to prove this hypothesis, and no studies have shown that adjuvanted vaccines are riskier than non-adjuvanted vaccines.
To reduce the risk of FISS, veterinarians are placing vaccines in sites that would make tumour removal easier, such as low on the leg instead of the interscapular space. Additionally, guidelines from the American Animal Hospital Association and Feline Veterinary Medical Association reflect recommendations on vaccinating cats based on their specific needs, local epidemiological factors, and manufacturer directions.
Vaccine Archives: Battling Bacteria
You may want to see also
Explore related products
Tumour removal is easier when the vaccine is administered in the lower distal limbs
Tumour removal is a common treatment for cancer in limbs. The main surgical goal is to remove the tumour, either by excising it with wide margins through a site clear of malignant growth or by completely removing the afflicted bone or compartment. The size of the tumour and its location on the limb are important factors in planning the reconstruction.
Veterinarians are increasingly placing vaccines in sites that would make tumour removal easier should a FISS (feline injection-site sarcoma) occur. For example, the lower distal limbs, such as placement low on the leg, are preferred over the interscapular space or the tail. This is because, in the past, amputations for cancer were done in a radical fashion, leaving little residual limb, except when amputating for very distal limb tumours. Thus, lower-limb amputations for cancer involving the knee joint or thigh were frequently performed by a hip disarticulation or hemipelvectomy.
The basic clinical rule was to amputate proximally to the joint immediately above the tumour site. However, modern diagnostic techniques can now demonstrate the presence or absence of metastases with a high degree of accuracy. Less extensive amputation techniques can now be employed, such as cross-bone amputation. Limb salvage by extended local or regional excision and reconstruction has become the principal goal, and limb salvage results in a better functional outcome compared to amputation.
While maximum preservation of limb length is desirable, certain amputation levels may result in residual limbs that are difficult to fit and, therefore, should be avoided, such as the hind foot, the distal third of the leg, and the femoral supracondylar region. It is critical to preserve the knee joint, if possible, to ensure smoothness of gait, lower energy cost, and better function.
Herpes in Kittens: Can Vaccinations Offer Protection?
You may want to see also
Explore related products
The risk of postvaccinal sarcoma is estimated at between 1 in 1,000 and 1 in 10,000 vaccinations
The introduction of non-adjuvanted vaccines, such as Purevax, has not significantly reduced the prevalence of postvaccinal sarcomas. This may be due to their higher cost and approval for annual use only, while traditional adjuvanted vaccines are cheaper and approved for use every 3 to 4 years. However, to mitigate the risk of postvaccinal sarcoma, some veterinarians choose to place vaccines in sites that would make tumor removal easier, such as low on the leg instead of the interscapular space.
Postvaccinal sarcomas, also known as vaccine-associated sarcomas (VAS) or feline injection-site sarcomas (FISS), are malignant tumors found in cats and, occasionally, dogs and ferrets. They are associated with certain vaccines, particularly rabies and feline leukemia virus vaccines, and have been linked to aluminum adjuvants in these vaccines. VAS typically appears as a rapidly growing, large, and firm mass in and under the skin, often containing fluid-filled cavities due to its rapid growth. It is diagnosed through a biopsy, and treatment options include surgical excision and immunotherapy.
While the risk of postvaccinal sarcoma is small, it is an uncommon but serious adverse reaction to vaccinations. Tumor growth can occur weeks, months, or even years after vaccination, and these tumors can invade local tissue and metastasize to other areas, leading to a poor prognosis. Therefore, it is essential to monitor cats for any lumps or swellings that persist or grow larger after vaccination and consult a veterinarian if necessary.
Vaccines and the Bible: What Does Scripture Say?
You may want to see also
Explore related products
The introduction of Purevax, the first non-adjuvanted canarypox-vectored rabies vaccine, in 2000
The introduction of Purevax in 2000 marked a significant development in the effort to reduce the risk of vaccine-associated feline sarcomas. Purevax is the first non-adjuvanted canarypox-vectored rabies vaccine for cats, developed by Mérial in Duluth, Georgia, USA. Its introduction was in response to the recognition of feline injection-site sarcomas (FISS) and the search for safer alternatives to adjuvanted vaccines.
FISS is an uncommon but serious adverse reaction that can occur at injection sites, including vaccination sites. While vaccines are crucial for protecting cats from potentially fatal diseases, the risk of FISS has been a concern for cat owners and veterinarians. Studies suggest that the inflammation associated with vaccine administration is a more likely cause of FISS than the disease-causing organisms themselves.
The introduction of Purevax was preceded by recommendations for changes in vaccination protocols and increased research on vaccine immunity duration. This research helped avoid over-vaccination and reduce unnecessary risks to patients. Veterinarians also started placing vaccines in sites that would make tumour removal easier, such as the lower distal limbs, in case FISS occurred.
The risk of postvaccinal sarcoma is estimated to be between 1 in 1000 and 1 in 10,000 vaccinations. While this risk is small, it has raised ethical questions about the continued use of adjuvanted products. Some studies suggest that non-adjuvanted vaccines may be less likely to induce sarcomas, but more research is needed to confirm this. The Task Force currently believes there is insufficient evidence to recommend a single vaccine type, and the decision should be made based on the cat's specific needs and local epidemiological factors.
China's COVID-19 Vaccine: What You Need to Know
You may want to see also
Frequently asked questions
Purevax is the first non-adjuvanted canarypox-vectored rabies vaccine for cats.
FISS stands for Feline Injection-Site Sarcoma. It is a rare but serious adverse reaction that can occur with injections, including vaccines.
The risk of FISS is estimated to be between 1 in 1000 and 1 in 10,000 vaccinations. The rate of metastasis of these sarcomas ranges from 10% to 28%.
There is currently insufficient research to recommend a single vaccine type in terms of FISS risk. However, one study suggests that non-adjuvanted vaccines may be less likely to induce sarcomas than adjuvanted vaccines.
